Abstract
Phenotypic assays measure the susceptibility of HIV-1 to antiretroviral drugs, and are used to guide treatment regimen choices. Analyses of baseline predictors of virological failure support the use of a 0.4-fold cutpoint for defining increased susceptibility (hypersusceptibility) to efavirenz in the PhenoSense HIV assay. The enhancement of the virological activity of efavirenz, associated with resistance to reverse transcriptase inhibitors, provides an opportunity to consider mutational and drug interactions in optimizing treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
